Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Milestone Pharmaceuticals (MIST) Net Income towards Common Stockholders: 2020-2021

Historic Net Income towards Common Stockholders for Milestone Pharmaceuticals (MIST) over the last 2 years, with Dec 2021 value amounting to -$42.9 million.

  • Milestone Pharmaceuticals' Net Income towards Common Stockholders fell 2.33% to -$14.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$58.2 million, marking a year-over-year change of. This contributed to the annual value of -$42.9 million for FY2021, which is 14.24% up from last year.
  • According to the latest figures from FY2021, Milestone Pharmaceuticals' Net Income towards Common Stockholders is -$42.9 million, which was up 14.24% from -$50.0 million recorded in FY2020.
  • Milestone Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$42.9 million for FY2021, and its period low was -$50.0 million during FY2020.
  • For the 2-year period, Milestone Pharmaceuticals' Net Income towards Common Stockholders averaged around -$46.4 million, with its median value being -$46.4 million (2020).
  • Data for Milestone Pharmaceuticals' Net Income towards Common Stockholders shows a peak YoY increased of 14.24% (in 2021) over the last 5 years.
  • Over the past 2 years, Milestone Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$50.0 million in 2020, then rose by 14.24% to -$42.9 million in 2021.